GIOTRIF® (afatinib) as monotherapy is indicated for patients with NSCLC of squamous histology progressing on or after platinum-based chemotherapy1
See the efficacy benefits of using GIOTRIF® (afatinib) after chemotherapy in unselected 2nd-line SqCC.2 Click here.
A comprehensive genomic analysis of 178 squamous cell carcinoma tumours by the Cancer Genome Atlas Research Network identified a potentially targetable gene or pathway alteration in 96% samples studied2
FGF=fibroblast growth factor receptor, JAKS, Janus Kinase, NSCLC=non-small-cell lung cancer, PI3K=phosphoinositide, SqCC=squamous cell carcinoma
You're now leaving our website...
Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.
Click here for general international information about afatinib for non-small-cell lung cancer treatment.